Larimar completes BLA submission for nomlabofusp in Friedreich's ataxia, seeking accelerated approval
The US biotech is relying on skin frataxin as a novel surrogate endpoint and expects the FDA's filing decision in early 2027, with approval targeted for mid-2027.
Larimar Therapeutics has completed its rolling Biologics License Application (BLA) to the US Food and Drug Administration for nomlabofusp, seeking accelerated approval in adults and children with Friedreich's ataxia. The company disclosed the milestone on 16 November 2026 alongside its third-quarter 2026 update.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Larimar Therapeutics, Inc. ↗
Article written by VigiEye from the official source (Larimar Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.